Pulse Biosciences Misses Q3 2026 Estimates as Revenue Rises 359% to $395K
Revenue of $395K vs. $521K expected and adjusted EPS of -$0.32 vs. -$0.31; revenue up 359% from a year earlier.
Pulse Biosciences (PLSE) missed estimates for the third quarter of 2026 on both revenue and adjusted EPS. Revenue was $395 thousand, up 359% from a year earlier, below the $521 thousand estimate, and adjusted EPS was -$0.32, down 10% from a year earlier, below the -$0.31 estimate.
Shares were unchanged in after-hours trading as of 4:04 p.m. ET, to $53.07 from a $53.07 close.
Q3 2026 scorecard
| Parameters | Expected | Actual | Beat/Miss |
|---|---|---|---|
| Adjusted EPS | -$0.31 | -$0.32 | Miss by 3.4% |
| Revenue | $521K | $395K | Miss by 24% |
| Change | YoY | QoQ |
|---|---|---|
| Adjusted EPS | ▼ 10% | ▲ 11% |
| Revenue | ▲ 359% | ▼ 9.0% |
By our calculation, revenue was $126 thousand below the estimate and adjusted EPS was $0.01 below it. The QoQ column compares with the previous quarter's revenue of $434 thousand and adjusted EPS of -$0.36. The YoY column compares with $86 thousand and -$0.29 in the same quarter a year earlier.
Track record
- EPS record. Adjusted EPS beat the estimate in 4 of the last 7 reports, including this one.
- Revenue record. Revenue beat the estimate in 2 of the last 5 reports.
- Revenue trend. Revenue over the last 5 reports, oldest first: $86 thousand, $264 thousand, $400 thousand, $434 thousand and $395 thousand.
What to watch
- Next-quarter estimates. Consensus calls for EPS of -$0.32 and revenue of $695 thousand next quarter, based on 2 analysts.
- Revenue growth. Whether revenue keeps growing from a year earlier after this quarter's 359% increase to $395 thousand.
- Estimate record. Whether Pulse Biosciences extends a record of beating EPS estimates in 4 of its last 7 reports.
- Related coverage. See our reports on Five9, Paylocity, ICU Medical and WillScot.
Sources: Results are from Pulse Biosciences's Nov. 5, 2026 quarterly report. Estimates are consensus figures. The prior-quarter and year-ago comparison figures are from Pulse Biosciences's earlier quarterly reports. Items labeled by our calculation are our own arithmetic. This article is informational only and is not investment advice.
Readers also read
Five9 Beats Q3 2026 Estimates as Revenue Rises 13% to $323.3M
EarningsPaylocity Beats Fiscal Q1 2027 Estimates as Revenue Rises 11% to $451.7M
EarningsICU Medical Beats Q3 2026 Estimates as Revenue Rises 4.4% to $560.4M
EarningsWillScot Beats Q3 2026 Estimates as Revenue Rises 6.1% to $601.3M
MarketCatalyst is not a registered investment advisor and does not manage client assets. Content on this platform is provided for informational and educational purposes only. It is not investment advice, and MarketCatalyst is not a stock-picking or trade-alert service. Trading stocks and options involves risk, including the possible loss of principal. Consider your own goals, time horizon, and risk tolerance, and consult a qualified financial advisor before making any investment decision.